Table 1 Participant characteristics.

From: Effects of rice bran arabinoxylan compound on quality of life of cancer patients during active treatment: a randomised placebo-controlled pilot trial

 

RBAC

Placebo

p value

N (available for analysis)

12 (100%)

17 (100%)

 

Age

68.8 ± 9.17

64.1 ± 7.35

p = 0.152

Sex

 Male

7 (58.3%)

14 (83.3%)

p = 0.218

 Female

5 (41.7%)

3 (17.7%)

 

Body composition

 Weight

79.0 ± 24.38

86.2 ± 18.26

p = 0.381

 Body Mass Index

27.6 ± 7.79

27.6 ± 4.67

p = 0.988

Primary cancer

 Lung

2 (16.7%)

6 (35.3%)

p = 0.268

 Melanoma

4 (33.4%)

2 (11.7%)

 

 Colon and Rectum

1 (8.3%)

4 (23.5%)

 

 Ovary and Uterus

3 (25.0%)

1 (5.9%)

 

 Bladder

1 (8.3%)

–

 

 Stomach

1 (8.3%)

–

 

 Breast

–

1 (5.9%)

 

 Oesophagus

–

1 (5.9%)

 

 Pleura

–

1 (5.9%)

 

 Kidney

–

1 (5.9%)

 

Cancer stage

 II

1 (8.4%)

1 (5.9%)

p = 0.847

 III

4 (33.3%)

8 (47.1%)

 

 IV

7 (58.3%)

8 (47.1%)

 

Recurrence

 No

7 (58.3%)

11 (64.7%)

p = 1.0

 Yes

5 (41.7%)

6 (32.3%)

 

Metastasis

   

 No

2 (16.7%)

4 (23.5%)

p = 1.0

 Yes

10 (83.3%)

13 (76.5%)

 

Treatment

 Chemotherapy

7 (58.3%)

12 (70.6%)

p = 0.694

 Immunotherapy

5 (41.7%)

5 (29.4%)

 

Lifestyle factors

 Diet (ARFS)

30.7 ± 8.51

33.5 ± 8.74

p = 0.456

 Physical activity (MET/week)

830.3 ± 601.7

706.5 ± 639.9

p = 0.399

 CAMQ score

15.8 ± 12.74

11.1 ± 12.41

p = 0.493

Trial status

 Withdrawn

1 (8.3%)

7 (41.2%)

p = 0.105

 Deceased

1 (8.3%)

1 (5.9%)

 

 Completed

10 (83.4%)

9 (52.9%)

 
  1. All continuous variables are presented as mean ± standard deviation, and the hypothesis testing of two means was based on the two-sided Student’s t-test. Significant testing of categorical variables was determined using Fisher’s exact test. ARFS = Australian recommended food score; CAMQ = Use of complementary and alternative medicine questionnaire; MET = metabolic equivalent of task; RBAC = rice bran arabinoxylan compound.
Back to article page